Pharmaceuticals & Therapeutics

NurExone appoints Eyal Gabbai, a healthcare and finance heavyweight, to its board, signaling a strategic pivot from R&D to market execution for its therapies.

Shane Kovacs's exit from Olema Oncology introduces leadership questions as the biotech firm nears a pivotal data readout for its lead breast cancer drug.

With its third Forbes nod, Jackson Healthcare's mix of strategic growth, tech, and culture reveals a model for navigating the healthcare crisis.

Promising Phase 2 data for a potential first-in-class neuropathic corneal pain therapy to be showcased, offering new hope for a debilitating condition.

After selling its proteomics arm to Illumina for $350M+, Standard BioTools is flush with cash but faces a pivotal moment to fix its core business.

ALX Oncology data shows CD47 levels predict response to evorpacept, offering new hope for heavily pretreated patients in a crowded therapeutic landscape.

Ruxolitinib cream's landmark approval in China marks a new era for vitiligo treatment, impacting patients, markets, and regulatory policy.

Facing a cash crunch after a major clinical trial setback, the cancer vaccine developer is exploring a sale or merger, putting its pipeline at risk.

After Amgen steps back, Kyowa Kirin takes full control of its promising atopic dermatitis drug, rocatinlimab, betting on its unique science.

Following the departure of its R&D head, Immunocore streamlines leadership, betting on internal experts to drive its next wave of innovative therapies.

With stronger Phase 2 data for its ATH434 drug and a healthy cash reserve, Alterity Therapeutics is preparing for a pivotal trial and seeking partners.

Tonix Pharmaceuticals' newly approved drug, TONMYA, offers a breakthrough for millions, using unique science to combat the chronic pain of fibromyalgia.

Lexicon Pharmaceuticals raised nearly $95 million to fund its drug pipeline, but the move sent its stock plunging as investors weighed future promise against immediate dilution.

After teetering on the brink, Poxel SA has secured court approval for a complex recovery plan, offering a lifeline for its innovative metabolic drug pipeline.

New data on Idorsia's lucerastat reveals potential to slow kidney decline in Fabry disease, offering a new path for an oral, genotype-independent therapy.

Houston biotech PranaX has closed an oversubscribed $17M Series A, signaling strong investor faith in its exosome-based approach to redefining quality of life.

A groundbreaking implantable cell therapy shows consistent, positive results for a debilitating complication of Crohn's disease, paving an expedited path to market.

With its acquisition offer falling short of a majority, Cycle Pharma extends its tender for Applied Therapeutics, leaving the company's fate in the balance.

A new report warns US drug price controls could mirror Canada's struggles, delaying access to new medicines. Is America trading innovation for affordability?

A new center in China is using a novel drug and special policies to offer hope against NUT carcinoma, a rare and deadly cancer affecting the young.